Alto Neuroscience (NYSE:ANRO) Stock Price Up 8.8% – Still a Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) shares rose 8.8% during trading on Monday . The stock traded as high as $24.61 and last traded at $24.78. Approximately 167,857 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 254,385 shares. The stock had previously closed at $22.78.

Analyst Ratings Changes

ANRO has been the topic of several analyst reports. BTIG Research raised their target price on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Wedbush reduced their price target on shares of Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, April 2nd. JonesTrading reduced their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a research note on Thursday, April 2nd. Finally, Wall Street Zen lowered shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Alto Neuroscience Trading Up 0.3%

The company has a market capitalization of $824.95 million, a price-to-earnings ratio of -11.84 and a beta of 2.01. The firm has a 50-day moving average price of $20.29 and a 200-day moving average price of $15.90. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.11. As a group, sell-side analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC acquired a new position in shares of Alto Neuroscience during the 1st quarter valued at $52,000. Torren Management LLC acquired a new position in shares of Alto Neuroscience during the 4th quarter valued at $62,000. Invesco Ltd. acquired a new position in shares of Alto Neuroscience during the 1st quarter valued at $67,000. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock worth $69,000 after acquiring an additional 2,055 shares during the last quarter. Finally, Bridgeway Capital Management LLC grew its holdings in shares of Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after acquiring an additional 25,000 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.